Efficacy and Safety of Chemotherapy in Elderly Patients with Unresectable Pancreatic Cancer
Open Access
- 8 May 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3334
Abstract
Background/Aims: The incidence of pancreatic cancer (PC) is gradually increasing among elderly individuals, but there are insufficient clinical data on elderly individuals. To determine the efficacy and safety of chemotherapy, we compared the. the outcomes of elderly patients with unresectable PC. Methods: We enrolled patients aged 75 years or older diagnosed with PC from 1 January 2010 to 30 November 2021. Propensity score matching (PSM) was used to reduce the heterogeneity of the study population. For efficacy evaluation, the median overall survival (OS) was estimated for the chemotherapy and nonchemotherapy groups. Chemotherapy tolerability evaluations were also investigated. Results: The study included 115 patients, 47 of whom received chemotherapy and 68 who did not. After PSM, compared with the nonchemotherapy group, the chemotherapy group had more myocardial infarctions (14.6 vs. 0.0%, p < 0.001) and chronic obstructive pulmonary disease (4.4 vs. 0.0%, p = 0.043). The primary endpoint, median OS, was significantly different in the with vs. without chemotherapy groups (203 vs. 106 days, p = 0.013). In the chemotherapy group, 10 patients (21.3%) discontinued treatment due to adverse events. However, there were no reports of death due to severe adverse events. Conclusions: This study demonstrated that chemotherapy improved median OS among elderly patients. These data could support the use of chemotherapy for elderly patients with unresectable PC.Keywords
This publication has 33 references indexed in Scilit:
- Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)Surgery, 2014
- Pancreatic Cancer Survival in Elderly Patients Treated With ChemotherapyPancreas, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survivalMolecular and Clinical Oncology, 2013
- Relationship goals of middle-aged, young-old, and old-old internet daters: An analysis of online personal adsJournal of Aging Studies, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Gemcitabine in elderly patients with advanced pancreatic cancerWorld Journal of Gastroenterology, 2011
- Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinomaJournal of Gastroenterology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987